AKTX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 23:00):

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases...

Stats
Dzisiejszy wolumen	22 004.00
Średni wolumen	11 858.00
Kapitalizacja rynkowa	7.84M
EPS	$2.00 ( 2023-10-03 )
Następna data zysków	( $0 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.630
ATR14	$0.0270 (2.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-01	Jacques Rachelle Suzanne	Sell	0	Ordinary Shares, par value $0.0001 per share
2024-01-01	Jacques Rachelle Suzanne	Sell	29 762 300	Stock Option (Right to Buy)
2023-06-01	Jacques Rachelle Suzanne	Sell	152 690 700	Stock Option (Right to Buy)
2024-07-17	Dicicco Wendy F	Sell	5 000 000	Stock Option (Right to Buy)
2024-01-01	Patel Samir Rashmikant	Buy	0	Ordinary Shares, par value $0.0001 per share

INSIDER POWER
-100.00
Last 82 transactions
Buy: 68 941 813 \| Sell: 428 362 177

Akari Therapeutics PLC Korelacja

10 Najbardziej pozytywne korelacje
SWVL	0.972
NAKD	0.968
SNGX	0.964
GROM	0.963
DIBS	0.963
AVIR	0.962
CSSE	0.962
JAGX	0.962
PSTX	0.961
RUBY	0.96

10 Najbardziej negatywne korelacje
AGZD	-0.97
DXJS	-0.965
TIGO	-0.958
PRAA	-0.954
PDFS	-0.95
GPACU	-0.948
MEOH	-0.947
UNAM	-0.945
SLMBP	-0.945
PANL	-0.944

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Akari Therapeutics PLC Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-4 000.00 (0.00 %)
EPS:	$-2.04

FY	2023
Przychody:	$0
Zysk brutto:	$-4 000.00 (0.00 %)
EPS:	$-2.04

FY	2022
Przychody:	$0
Zysk brutto:	$-3 708.00 (0.00 %)
EPS:	$-2.23

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.406

Financial Reports:

No articles found.

Akari Therapeutics PLC

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.